Docetaxel and cisplatin in head and neck cancer [1]

Annals of Oncology

Volumn 11, Issue 12, 2000, Pages 1617-1618

  Schjki, P ^a   Wanders, J ^a   Verweij, J ^a   Fumoleau, P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; MAGNESIUM; MANNITOL; METHYLPREDNISOLONE; PREDNISOLONE;

CLINICAL TRIAL; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; HYDRATION; HYPOMAGNESEMIA; KIDNEY INJURY; LETTER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DIURETICS; HEAD AND NECK NEOPLASMS; HUMANS; KIDNEY TUBULES; MAGNESIUM; MAGNESIUM DEFICIENCY; PACLITAXEL; TAXOIDS;

EID: 0034486753     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008301513627     Document Type: Letter

References (4)

1. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck
2. Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous-cell carcinoma of the head and neck
3. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial
4. A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil